Modified Finnegan Neonatal Abstinence Score (NAS)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- No Treatment0–7
- Monitor Closely8–11
- Treat12–50
The Modified Finnegan Neonatal Abstinence Score (NAS) calculates calculating weight-based pediatric dosing and evaluating age-specific physiological parameters. Key inputs include cry. Scores guide titrating weight-adjusted medication dosing, monitoring developmental safety, and evaluating treatment response. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies severity of opioid withdrawal in neonates and guides pharmacologic treatment decisions
Clinical Indication
The Modified Finnegan Neonatal Abstinence Score (NAS) is indicated for bedside clinical practice to support Stratifies severity of opioid withdrawal in neonates and guides pharmacologic treatment decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Neonates, infants, children, and adolescents from birth up to 18 years of age. Clinical application is indicated across Pediatric emergency departments, pediatric inpatient wards, PICU, and pediatric primary care.
Limitations & Contraindications
Adult scoring thresholds and pharmacological formulas must never be applied to pediatric patients.
Clinical Pearls & Action Plan
Accurate weight-based dosing and age-stratified physiological vital sign reference ranges are foundational in pediatric clinical practice. Guideline pearl: Two consecutive scores ≥12 OR three consecutive scores ≥8 indicate need for pharmacologic treatment.
Sum of points from all assessed categories: CNS disturbances (cry, sleep, reflexes, tremors, tone, excoriation, jerks, convulsions), metabolic/vasomotor (sweating, fever, yawning, mottling), respiratory (flaring, rate, sneezing, stuffiness), and GI (feeding, vomiting, stools).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| cry | string | Yes | Crying pattern assessment |
| sleep | string | Yes | Sleep duration after feeding |
| moro_reflex | string | Yes | Moro reflex activity assessment |
| tremors | string | Yes | Tremor severity and occurrence |
| increased_muscle_tone | string | Yes | Presence of increased muscle tone |
| excoriation | string | Yes | Presence of skin excoriation from excessive movement |
| myoclonic_jerks | string | Yes | Presence of myoclonic jerks |
| generalized_convulsions | string | Yes | Presence of generalized convulsions |
| sweating | string | Yes | Presence of excessive sweating |
| hyperthermia | string | Yes | Body temperature elevation |
| frequent_yawning | string | Yes | Frequent yawning (>3-4 times per interval) |
| mottling | string | Yes | Presence of skin mottling |
| nasal_flaring | string | Yes | Presence of nasal flaring |
| respiratory_rate | string | Yes | Respiratory rate and retractions |
| sneezing | string | Yes | Frequent sneezing (>3-4 times per interval) |
| nasal_stuffiness | string | Yes | Presence of nasal stuffiness |
| excessive_sucking | string | Yes | Excessive or frantic sucking behavior |
| poor_feeding | string | Yes | Poor feeding with infrequent or uncoordinated suck |
| regurgitation | string | Yes | Regurgitation (≥2 times during/post feeding) |
| projectile_vomiting | string | Yes | Presence of projectile vomiting |
| loose_stools | string | Yes | Loose stools (curds/seedy) |
| watery_stools | string | Yes | Watery stools |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–7 | No Treatment | Mild or no withdrawal symptoms |
| 8–11 | Monitor Closely | Moderate withdrawal symptoms |
| 12–50 | Treat | Severe withdrawal symptoms |
Evidence-Based References (EBM)
- Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141-58.
- Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009 Jan-Feb;5(1):47-55.
- Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012 Feb;129(2):e540-60. doi: 10.1542/peds.2011-3212.DOI: 10.1542/peds.2011-3212